HER2 antibody therapy combined with conventional chemotherapy improved survival compared to chemotherapy alone in Phase III trials.

“So whatever you start with, so it's depending on the trial, a third to a half of the recurrences that would have occurred don't happen by the addition. This is, you're right to mention placebo, but by historical fact, in this case, everybody got chemo. Everybody gets the same, yeah, yeah, yeah. Yeah, chemo plus minus, if you will. So the addition of the HER2 antibody or not. And this is how many subsequent studies and other cancer types have been done to try to show the same kind of benefit of treating only microscopic or digital disease as opposed to overt metastatic disease. So a third to a half. reduction in risk of relapse over long periods of time now and stably so in the case of HER2.”